Last reviewed 2026-04-22 · How we verify

Comparison 1: Prehospital Ceftriaxone

Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Prehospital empiric treatment of serious bacterial infections, Meningitis, Sepsis.

At a glance

Mechanism of action

Ceftriaxone works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. It has broad-spectrum activity against gram-positive and gram-negative bacteria, making it suitable for empiric treatment of serious infections in prehospital settings. The drug is bactericidal and achieves good tissue penetration, including into the central nervous system.

Approved indications

• Prehospital empiric treatment of serious bacterial infections
• Meningitis
• Sepsis
• Community-acquired pneumonia

Common side effects

• Hypersensitivity reactions (rash, urticaria)
• Diarrhea
• Phlebitis at injection site
• Elevated liver enzymes
• Eosinophilia

Key clinical trials

• Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Comparison 1: Prehospital Ceftriaxone CI brief — competitive landscape report
• Comparison 1: Prehospital Ceftriaxone updates RSS · CI watch RSS
• Dr. Damon Scales portfolio CI